Harnessing endogenous stem cells to treat neurodegenerative
disorders of the basal ganglia
by
Mohapel P, Brundin P.
Section for Neuronal Survival,
Wallenberg Neuroscience Center,
BMC A-10, Lund University,
SE-221 84 Lund, Sweden.
paul.mohapel@neurol.lu.se
Parkinsonism Relat Disord. 2004 Jul;10(5):259-64

ABSTRACT

New neurons are continuously generated in selective regions of the normal adult mammalian brain. Recent evidence suggests that neural stem or progenitor cells located in the subventricular zone lining of the lateral ventricles can be induced to proliferate and migrate to the adjacent striatum following brain insults or growth factor treatment. This ability to incorporate new cells into the striatum gives the potential of repairing and restoring basal ganglia functions in Parkinson's and Huntington's diseases. The future challenges lay in directing these new cells to adopt the appropriate neuronal phenotypes and to re-establish proper connections and functional circuitry.

MAOIs
Rasagiline
Neuroprotection
Rasagiline: structure
MAO-b inhibitors/PD
Anti-apoptotic activity
Parkinson's disease: treatment
Antioxidant strategies against aging
Anti-Alzheimer/anti-Parkinson's drugs
Parkinson's disease and sleep disorders
Rasagiline/ anti-apoptotic bcl-2 gene family
Dual AChE and MAO inhibitors and Alzheimer's
Rasagiline v selegiline: neuronal survival effects
Rasagiline (Agilect) in early Parkinson's disease

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family